

REFERENCES

- Aly, A.S., Vaughan, A.M., Kappe, S.H., 2009. Malaria parasite development in the mosquito and infection of the mammalian host. *Annu Rev Microbiol* 63, 195-221.
- Baggott, J.E., Morgan, S.L., Ha, T.S., Alarcon, G.S., Koopman, W.J., Krumdieck, C.L., 1993. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. *Clin Exp Rheumatol* 11 Suppl 8, S101-105.
- Balu, B., Adams, J.H., 2007. Advancements in transfection technologies for *Plasmodium*. *Int J Parasitol* 37, 1-10.
- Bates, S.J., Winstanley, P.A., Watkins, W.M., Allouche, A., Bwika, J., Happi, T.C., Kremsner, P.G., Kublin, J.G., Premji, Z., Sibley, C.H., 2004. Rare, highly pyrimethamine-resistant alleles of the *Plasmodium falciparum* dihydrofolate reductase gene from 5 African sites. *The Journal of infectious diseases* 190, 1783-1792.
- Berkhout, B., 1999. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. *J Biomed Sci* 6, 298-305.
- Biles, B.D., Connolly, B.A., 2004. Low-fidelity *Pyrococcus furiosus* DNA polymerase mutants useful in error-prone PCR. *Nucleic Acids Res* 32, e176.
- Bzik, D.J., Li, W.B., Horii, T., Inselburg, J., 1987. Molecular cloning and sequence analysis of the *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase gene. *Proc Natl Acad Sci U S A* 84, 8360-8364.
- Cadwell, R.C., Joyce, G.F., 1992. Randomization of genes by PCR mutagenesis. *PCR Methods Appl* 2, 28-33.
- Carvalho, T.G., Menard, R., 2005. Manipulating the *Plasmodium* genome. *Current issues in molecular biology* 7, 39-55.
- Chanama, M., Chanama, S., Shaw, P.J., Chitnumsub, P., Leartsakulpanich, U., Yuthavong, Y., 2010. Formation of catalytically active cross-species heterodimers of thymidylate synthase from *Plasmodium falciparum* and *Plasmodium vivax*. *Mol Biol Rep* 38, 1029-1037.
- Childs, G.E., Lambros, C., 1986. Analogues of N-benzyloxydihydrotriazines: in vitro antimalarial activity against *Plasmodium falciparum*. *Ann Trop Med Parasitol* 80, 177-181.
- Chunduru, S.K., Cody, V., Luft, J.R., Pangborn, W., Appleman, J.R., Blakley, R.L., 1994. Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. *The Journal of biological chemistry* 269, 9547-9555.
- Chusacultanchai, S., Thiensathit, P., Tarnchompoo, B., Sirawaraporn, W., Yuthavong, Y., 2002. Novel antifolate resistant mutations of *Plasmodium falciparum* dihydrofolate reductase selected in *Escherichia coli*. *Mol Biochem Parasitol* 120, 61-72.

- Chusacultanachai, S., Yuthavong, Y., 2004. Random mutagenesis strategies for construction of large and diverse clone libraries of mutated DNA fragments. *Methods Mol Biol* 270, 319-334.
- Cirino, P.C., Mayer, K.M., Umeno, D., 2003. Generating mutant libraries using error-prone PCR. *Methods Mol Biol* 231, 3-9.
- Crabb, B.S., Cooke, B.M., Reeder, J.C., Waller, R.F., Caruana, S.R., Davern, K.M., Wickham, M.E., Brown, G.V., Coppel, R.L., Cowman, A.F., 1997. Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. *Cell* 89, 287-296.
- Crabb, B.S., Cowman, A.F., 1996. Characterization of promoters and stable transfection by homologous and nonhomologous recombination in *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 93, 7289-7294.
- Cruz, A., Beverley, S.M., 1990. Gene replacement in parasitic protozoa. *Nature* 348, 171-173.
- de Koning-Ward, T.F., Fidock, D.A., Thathy, V., Menard, R., van Spaendonk, R.M., Waters, A.P., Janse, C.J., 2000a. The selectable marker human dihydrofolate reductase enables sequential genetic manipulation of the *Plasmodium berghei* genome. *Mol Biochem Parasitol* 106, 199-212.
- de Koning-Ward, T.F., Janse, C.J., Waters, A.P., 2000b. The development of genetic tools for dissecting the biology of malaria parasites. *Annu Rev Microbiol* 54, 157-185.
- de Koning-Ward, T.F., Thomas, A.W., Waters, A.P., Janse, C.J., 1998. Stable expression of green fluorescent protein in blood and mosquito stages of *Plasmodium berghei*. *Mol Biochem Parasitol* 97, 247-252.
- Dechering, K.J., Kaan, A.M., Mbacham, W., Wirth, D.F., Eling, W., Konings, R.N., Stunnenberg, H.G., 1999. Isolation and functional characterization of two distinct sexual-stage-specific promoters of the human malaria parasite *Plasmodium falciparum*. *Mol Cell Biol* 19, 967-978.
- Dechering, K.J., Thompson, J., Dodemont, H.J., Eling, W., Konings, R.N., 1997. Developmentally regulated expression of *pfs16*, a marker for sexual differentiation of the human malaria parasite *Plasmodium falciparum*. *Mol Biochem Parasitol* 89, 235-244.
- Dittrich, S., Mitchell, S.L., Blagborough, A.M., Wang, Q., Wang, P., Sims, P.F., Hyde, J.E., 2008. An atypical orthologue of 6-pyruvoyltetrahydropterin synthase can provide the missing link in the folate biosynthesis pathway of malaria parasites. *Molecular microbiology* 67, 609-618.
- Doerig, C., Abdi, A., Bland, N., Eschenlauer, S., Dorin-Semblat, D., Fennell, C., Halbert, J., Holland, Z., Nivez, M.P., Semblat, J.P., Sicard, A., Reininger, L., 2009. Malaria: targeting parasite and host cell kinomes. *Biochim Biophys Acta* 1804, 604-612.
- Donald, R.G., Carter, D., Ullman, B., Roos, D.S., 1996. Insertional tagging, cloning, and expression of the *Toxoplasma gondii* hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. *J Biol Chem* 271, 14010-14019.

- Donald, R.G., Roos, D.S., 1993. Stable molecular transformation of *Toxoplasma gondii*: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. *Proc Natl Acad Sci U S A* 90, 11703-11707.
- Dower, W.J., Miller, J.F., Ragsdale, C.W., 1988. High efficiency transformation of *E. coli* by high voltage electroporation. *Nucleic Acids Res* 16, 6127-6145.
- Duangrudee, T., 2004. Crystal structure of *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase in complex with trimethoprim. Mahidol University, Graduate Studies.
- Eid, J., Sollner-Webb, B., 1991. Stable integrative transformation of *Trypanosoma brucei* that occurs exclusively by homologous recombination. *Proc Natl Acad Sci U S A* 88, 2118-2121.
- Elion, G.B., Hitchings, G.H., 1950. Antagonist of nucleic acid derivatives. III. The specificity of the purine requirement of *Lactobacillus casei*. *J Biol Chem* 185, 651-655.
- Emond, S., Mondon, P., Pizzut-Serin, S., Douchy, L., Crozet, F., Bouayadi, K., Kharrat, H., Potocki-Veronese, G., Monsan, P., Remaud-Simeon, M., 2008. A novel random mutagenesis approach using human mutagenic DNA polymerases to generate enzyme variant libraries. *Protein Eng Des Sel* 21, 267-274.
- Esposito, R., 1991. [Chemoprophylaxis and chemotherapy of malaria in the 90s]. *G Ital Chemioter* 38, 75-77.
- Ferlan, J.T., Mookherjee, S., Okezie, I.N., Fulgence, L., Sibley, C.H., 2001. Mutagenesis of dihydrofolate reductase from *Plasmodium falciparum*: analysis in *Saccharomyces cerevisiae* of triple mutant alleles resistant to pyrimethamine or WR99210. *Molecular and biochemical parasitology* 113, 139-150.
- Fernandez, A., Tawfik, D.S., Berkhout, B., Sanders, R., Kloczkowski, A., Sen, T., Jernigan, B., 2005. Protein promiscuity: drug resistance and native functions--HIV-1 case. *J Biomol Struct Dyn* 22, 615-624.
- Fidock, D.A., Nomura, T., Wellems, T.E., 1998. Cycloguanil and its parent compound proguanil demonstrate distinct activities against *Plasmodium falciparum* malaria parasites transformed with human dihydrofolate reductase. *Mol Pharmacol* 54, 1140-1147.
- Fidock, D.A., Wellems, T.E., 1997. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. *Proc Natl Acad Sci U S A* 94, 10931-10936.
- Foote, S.J., Galatis, D., Cowman, A.F., 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum* involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. *Proc Natl Acad Sci U S A* 87, 3014-3017.
- Franke-Fayard, B., Trueman, H., Ramesar, J., Mendoza, J., van der Keur, M., van der Linden, R., Sinden, R.E., Waters, A.P., Janse, C.J., 2004. A *Plasmodium berghei* reference line that constitutively expresses GFP at a high level throughout the complete life cycle. *Molecular and biochemical parasitology* 137, 23-33.

- Galivan, J., Nimec, Z., Rhee, M., Boschelli, D., Oronsky, A.L., Kerwar, S.S., 1988. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. *Cancer Res* 48, 2421-2425.
- Giraldo, L.E., Acosta, M.C., Labrada, L.A., Praba, A., Montenegro-James, S., Saravia, N.G., Krogstad, D.J., 1998. Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in *Plasmodium falciparum* from southwest Colombia. *Am J Trop Med Hyg* 59, 124-128.
- Goonewardene, R., Daily, J., Kaslow, D., Sullivan, T.J., Duffy, P., Carter, R., Mendis, K., Wirth, D., 1993. Transfection of the malaria parasite and expression of firefly luciferase. *Proc Natl Acad Sci U S A* 90, 5234-5236.
- Gregson, A., Plowe, C.V., 2005. Mechanisms of resistance of malaria parasites to antifolates. *Pharmacol Rev* 57, 117-145.
- Gresch, O., Engel, F.B., Nestic, D., Tran, T.T., England, H.M., Hickman, E.S., Korner, I., Gan, L., Chen, S., Castro-Obregon, S., Hammermann, R., Wolf, J., Muller-Hartmann, H., Nix, M., Siebenkotten, G., Kraus, G., Lun, K., 2004. New non-viral method for gene transfer into primary cells. *Methods* 33, 151-163.
- Hankins, E.G., Warhurst, D.C., Sibley, C.H., 2001. Novel alleles of the *Plasmodium falciparum* dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. *Molecular and biochemical parasitology* 117, 91-102.
- Hastings, M.D., Bates, S.J., Blackstone, E.A., Monks, S.M., Mutabingwa, T.K., Sibley, C.H., 2002. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of *Plasmodium falciparum* from Tanzania. *Trans R Soc Trop Med Hyg* 96, 674-676.
- Haynes, R.K., Chan, H.W., Ho, W.Y., Ko, C.K., Gerena, L., Kyle, D.E., Peters, W., Robinson, B.L., 2005. Convenient access both to highly antimalaria-active 10-arylaminoartemisinins, and to 10-alkyl ethers including artemether, arteether, and artelinate. *Chembiochem* 6, 659-667.
- Hitchings, G.H., Burchall, J.J., 1965. Inhibition of folate biosynthesis and function as a basis for chemotherapy. *Adv Enzymol Relat Areas Mol Biol* 27, 417-468.
- Hitchings, G.H., Falco, E.A., Elion, G.B., Singer, S., Waring, G.B., Hutchison, D.J., Burchenal, J.H., 1952a. 2, 4-Diaminopyrimidines as antagonists of folic acid and folinic acid. *Arch Biochem Biophys* 40, 479-481.
- Hitchings, G.H., Falco, E.A., Vanderwerff, H., Russell, P.B., Elion, G.B., 1952b. Antagonists of nucleic acid derivatives. VII. 2, 4-Diaminopyrimidines. *J Biol Chem* 199, 43-56.
- Horrocks, P., Kilbey, B.J., 1996. Physical and functional mapping of the transcriptional start sites of *Plasmodium falciparum* proliferating cell nuclear antigen. *Mol Biochem Parasitol* 82, 207-215.
- Horrocks, P., Lanzer, M., 1999. Mutational analysis identifies a five base pair cis-acting sequence essential for GBP130 promoter activity in *Plasmodium falciparum*. *Mol Biochem Parasitol* 99, 77-87.
- Hunt, S.Y., Detering, C., Varani, G., Jacobus, D.P., Schiehsler, G.A., Shieh, H.M., Nevchas, I., Terpinski, J., Sibley, C.H., 2005. Identification of the optimal third generation antifolate against *P. falciparum* and *P. vivax*. *Mol Biochem Parasitol* 144, 198-205.

- Hurly, M.G., 1959. Potentiation of pyrimethamine by sulphadiazine in human malaria. *Trans R Soc Trop Med Hyg* 53, 412-413.
- Hyde, J.E., 1990. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. *Pharmacol Ther* 48, 45-59.
- Hyde, J.E., 2005. Exploring the folate pathway in *Plasmodium falciparum*. *Acta tropica* 94, 191-206.
- Ivanetich, K.M., Santi, D.V., 1990. Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. *FASEB J* 4, 1591-1597.
- Janse, C.J., Camargo, A., Del Portillo, H.A., Herrera, S., Kumlien, S., Mons, B., Thomas, A., Waters, A.P., 1994. Removal of leucocytes from *Plasmodium vivax*-infected blood. *Ann Trop Med Parasitol* 88, 213-216.
- Janse, C.J., Franke-Fayard, B., Mair, G.R., Ramesar, J., Thiel, C., Engelmann, S., Matuschewski, K., van Gemert, G.J., Sauerwein, R.W., Waters, A.P., 2006a. High efficiency transfection of *Plasmodium berghei* facilitates novel selection procedures. *Mol Biochem Parasitol* 145, 60-70.
- Janse, C.J., Franke-Fayard, B., Waters, A.P., 2006b. Selection by flow-sorting of genetically transformed, GFP-expressing blood stages of the rodent malaria parasite, *Plasmodium berghei*. *Nature protocols* 1, 614-623.
- Janse, C.J., Ramesar, J., Waters, A.P., 2006c. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite *Plasmodium berghei*. *Nat Protoc* 1, 346-356.
- Janse, C.J., Waters, A.P., 1995. *Plasmodium berghei*: the application of cultivation and purification techniques to molecular studies of malaria parasites. *Parasitol Today* 11, 138-143.
- Japrun, D., Leartsakulpanich, U., Chusacultanchai, S., Yuthavong, Y., 2007. Conflicting requirements of *Plasmodium falciparum* dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. *Antimicrob Agents Chemother* 51, 4356-4360.
- Kain, K.C., Shanks, G.D., Keystone, J.S., 2001. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. *Clin Infect Dis* 33, 226-234.
- Kamen, B., 1997. Folate and antifolate pharmacology. *Semin Oncol* 24, S18-30-S18-39.
- Keuth, U., Sabbagh, M., Thesen, E., 1970. [Therapy of bacterial infections in infants and children. Report of 171 cases treated with trimethoprim-sulfamethoxazol]. *Munch Med Wochenschr* 112, 802-806.
- Knapen, M.F., van der Wildt, B., Sijtsma, E.G., Peters, W.H., Roelofs, H.M., Steegers, E.A., 1999. Glutathione S-transferase Alpha 1-1 and aminotransferases in umbilical cord blood. *Early Hum Dev* 54, 129-135.
- Krungkrai, J., Yuthavong, Y., Webster, H.K., 1989. High-performance liquid chromatographic assay for thymidylate synthase from the human malaria parasite, *Plasmodium falciparum*. *J Chromatogr* 487, 51-59.
- Leclere, P.G., Panjwani, A., Docherty, R., Berry, M., Pizzey, J., Tonge, D.A., 2005. Effective gene delivery to adult neurons by a modified form of electroporation. *J Neurosci Methods* 142, 137-143.

- Lee, M.G., Van der Ploeg, L.H., 1990. Homologous recombination and stable transfection in the parasitic protozoan *Trypanosoma brucei*. *Science* 250, 1583-1587.
- Lemcke, T., Christensen, I.T., Jorgensen, F.S., 1999. Towards an understanding of drug resistance in malaria: three-dimensional structure of *Plasmodium falciparum* dihydrofolate reductase by homology building. *Bioorg Med Chem* 7, 1003-1011.
- Lobo, C.A., Fujioka, H., Aikawa, M., Kumar, N., 1999. Disruption of the Pfg27 locus by homologous recombination leads to loss of the sexual phenotype in *P. falciparum*. *Mol Cell* 3, 793-798.
- Maasho, K., Marusina, A., Reynolds, N.M., Coligan, J.E., Borrego, F., 2004. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system. *J Immunol Methods* 284, 133-140.
- Maciel, C., de Oliveira Junior, V.X., Fazio, M.A., Nacif-Pimenta, R., Miranda, A., Pimenta, P.F., Capurro, M.L., 2008. Anti-plasmodium activity of angiotensin II and related synthetic peptides. *PLoS One* 3, e3296.
- Mandel, M., Higa, A., 1970. Calcium-dependent bacteriophage DNA infection. *J Mol Biol* 53, 159-162.
- Martin, D.C., Arnold, J.D., 1968. Treatment of acute falciparum malaria with sulfalene and trimethoprim. *JAMA* 203, 476-480.
- McGregor, I.A., Williams, K., Goodwin, L.G., 1963. Pyrimethamine and Sulphadiazine in Treatment of Malaria. *Br Med J* 2, 728-729.
- McGuire, J.J., 2003. Anticancer antifolates: current status and future directions. *Curr Pharm Des* 9, 2593-2613.
- McKie, J.H., Douglas, K.T., Chan, C., Roser, S.A., Yates, R., Read, M., Hyde, J.E., Dascombe, M.J., Yuthavong, Y., Sirawaraporn, W., 1998. Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. *J Med Chem* 41, 1367-1370.
- Meisner, H., Carter, J.R., Jr., 1977. Regulation of lipolysis in adipose tissue. *Horizons in biochemistry and biophysics* 4, 91-129.
- Michel, R., 1968. [Comparative study of the association of sulfalene and pyrimethamine and of sulfalene alone in mass chemoprophylaxis of malaria]. *Med Trop (Mars)* 28, 488-494.
- Nash, L.A., Peterson, L.N., Nadler, S.P., Levine, D.Z., 1988. Determination of sodium and potassium in nanoliter volumes of biological fluids by furnace atomic absorption spectrometry. *Anal Chem* 60, 2413-2418.
- Neylon, C., 2004. Chemical and biochemical strategies for the randomization of protein encoding DNA sequences: library construction methods for directed evolution. *Nucleic Acids Res* 32, 1448-1459.
- Nunes, A., Thathy, V., Bruderer, T., Sultan, A.A., Nussenzweig, R.S., Menard, R., 1999. Subtle mutagenesis by ends-in recombination in malaria parasites. *Mol Cell Biol* 19, 2895-2902.

- Nzila-Mounda, A., Mberu, E.K., Sibley, C.H., Plowe, C.V., Winstanley, P.A., Watkins, W.M., 1998. Kenyan *Plasmodium falciparum* field isolates: correlation between pyrimethamine and chlorocycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. *Antimicrob Agents Chemother* 42, 164-169.
- Nzila, A., 2006. The past, present and future of antifolates in the treatment of *Plasmodium falciparum* infection. *The Journal of antimicrobial chemotherapy* 57, 1043-1054.
- O'Donnell, R.A., Freitas-Junior, L.H., Preiser, P.R., Williamson, D.H., Duraisingh, M., McElwain, T.F., Scherf, A., Cowman, A.F., Crabb, B.S., 2002. A genetic screen for improved plasmid segregation reveals a role for Rep20 in the interaction of *Plasmodium falciparum* chromosomes. *The EMBO journal* 21, 1231-1239.
- Olliaro, P.L., Yuthavong, Y., 1999. An overview of chemotherapeutic targets for antimalarial drug discovery. *Pharmacol Ther* 81, 91-110.
- Orr-Weaver, T.L., Szostak, J.W., Rothstein, R.J., 1981. Yeast transformation: a model system for the study of recombination. *Proc Natl Acad Sci U S A* 78, 6354-6358.
- Peters, W., 1975. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of *P. berghei* in screening for blood schizontocidal activity. *Ann Trop Med Parasitol* 69, 155-171.
- Peters, W.H., te Morsche, R.H., Roelofs, H.M., Mathus-Vliegen, E.M., Berkhout, M., Nagengast, F.M., 2009. COX-2 polymorphisms in patients with familial adenomatous polyposis. *Oncol Res* 17, 347-351.
- Peterson, D.S., Milhous, W.K., Wellems, T.E., 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in *Plasmodium falciparum* malaria. *Proc Natl Acad Sci U S A* 87, 3018-3022.
- Peterson, D.S., Walliker, D., Wellems, T.E., 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in *falciparum* malaria. *Proc Natl Acad Sci U S A* 85, 9114-9118.
- Prendergast, N.J., Appleman, J.R., Delcamp, T.J., Blakley, R.L., Freisheim, J.H., 1989. Effects of conversion of phenylalanine-31 to leucine on the function of human dihydrofolate reductase. *Biochemistry* 28, 4645-4650.
- Rastelli, G., Sirawaraporn, W., Sompornpisut, P., Vilaivan, T., Kamchonwongpaisan, S., Quarrell, R., Lowe, G., Thebtaranonth, Y., Yuthavong, Y., 2000. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with *Plasmodium falciparum* dihydrofolate reductase: structural basis of antifolate resistance. *Bioorg Med Chem* 8, 1117-1128.
- Rothstein, R., 1991. Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast. *Methods Enzymol* 194, 281-301.
- Scherer, S., Davis, R.W., 1979. Replacement of chromosome segments with altered DNA sequences constructed in vitro. *Proc Natl Acad Sci U S A* 76, 4951-4955.

- Schlitzer, M., 2007. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. *ChemMedChem* 2, 944-986.
- Shafikhani, S., Siegel, R.A., Ferrari, E., Schellenberger, V., 1997. Generation of large libraries of random mutants in *Bacillus subtilis* by PCR-based plasmid multimerization. *Biotechniques* 23, 304-310.
- Shanks, G.D., Kain, K.C., Keystone, J.S., 2001. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. *Clin Infect Dis* 33, 381-385.
- Sibley, C.H., Hyde, J.E., Sims, P.F., Plowe, C.V., Kublin, J.G., Mberu, E.K., Cowman, A.F., Winstanley, P.A., Watkins, W.M., Nzila, A.M., 2001. Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends Parasitol* 17, 582-588.
- Singh, M., Ghose, T., Kralovec, J., Blair, A.H., Belitsky, P., 1991. Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model. *Cancer Immunol Immunother* 32, 331-334.
- Sirawaraporn, W., 1998. Dihydrofolate reductase and antifolate resistance in malaria. *Drug Resist Updat* 1, 397-406.
- Sirawaraporn, W., Sathitkul, T., Sirawaraporn, R., Yuthavong, Y., Santi, D.V., 1997. Antifolate-resistant mutants of *Plasmodium falciparum* dihydrofolate reductase. *Proc Natl Acad Sci U S A* 94, 1124-1129.
- Snewin, V.A., England, S.M., Sims, P.F., Hyde, J.E., 1989. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. *Gene* 76, 41-52.
- Soskine, M., Tawfik, D.S., 2010. Mutational effects and the evolution of new protein functions. *Nat Rev Genet* 11, 572-582.
- Soskine, M., Tawfik, D.S., 2010. Mutational effects and the evolution of new protein functions. *Nat Rev Genet* 11, 572-582.
- Spee, J.H., de Vos, W.M., Kuipers, O.P., 1993. Efficient random mutagenesis method with adjustable mutation frequency by use of PCR and dITP. *Nucleic Acids Res* 21, 777-778.
- Sultan, A.A., Thathy, V., Frevert, U., Robson, K.J., Crisanti, A., Nussenzweig, V., Nussenzweig, R.S., Menard, R., 1997. TRAP is necessary for gliding motility and infectivity of *Plasmodium* sporozoites. *Cell* 90, 511-522.
- Thathy, V., Menard, R., 2002. Gene targeting in *Plasmodium berghei*. *Methods Mol Med* 72, 317-331.
- Tomas, A.M., van der Wel, A.M., Thomas, A.W., Janse, C.J., Waters, A.P., 1998. Transfection systems for animal models of malaria. *Parasitol Today* 14, 245-249.
- Toyoda, T., Brobey, R.K., Sano, G., Horii, T., Tomioka, N., Itai, A., 1997. Lead discovery of inhibitors of the dihydrofolate reductase domain of *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase. *Biochem Biophys Res Commun* 235, 515-519.
- Urdaneta, L., Plowe, C., Goldman, I., Lal, A.A., 1999. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of *Plasmodium falciparum* isolates from Venezuela. *Am J Trop Med Hyg* 61, 457-462.

- van der Wel, A.M., Tomas, A.M., Kocken, C.H., Malhotra, P., Janse, C.J., Waters, A.P., Thomas, A.W., 1997. Transfection of the primate malaria parasite *Plasmodium knowlesi* using entirely heterologous constructs. *J Exp Med* 185, 1499-1503.
- van Dijk, M.R., Waters, A.P., Janse, C.J., 1995. Stable transfection of malaria parasite blood stages. *Science* 268, 1358-1362.
- Vasconcelos, K.F., Plowe, C.V., Fontes, C.J., Kyle, D., Wirth, D.F., Pereira da Silva, L.H., Zalis, M.G., 2000. Mutations in *Plasmodium falciparum* dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. *Memorias do Instituto Oswaldo Cruz* 95, 721-728.
- Volpato, J.P., Pelletier, J.N., 2009. Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison. *Drug Resist Updat* 12, 28-41.
- Walliker, D., Hunt, P., Babiker, H., 2005. Fitness of drug-resistant malaria parasites. *Acta tropica* 94, 251-259.
- Warhurst, D.C., 1998. Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance. *Drug discovery today* 3, 538-546.
- Watkins, W.M., Brandling-Bennett, A.D., Oloo, A.J., Howells, R.E., Gilles, H.M., Koech, D.K., 1987. Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. *Lancet* 1, 125-128.
- Wernsdorfer, W.H., 1990. Chemoprophylaxis of malaria: underlying principles and their realization. *Med Trop (Mars)* 50, 119-124.
- WHO, 2010. World malaria report 2010. WHO press.
- Winstanley, P.A., 2000. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. *Parasitol Today* 16, 146-153.
- Wu, Y., Sifri, C.D., Lei, H.H., Su, X.Z., Wellems, T.E., 1995. Transfection of *Plasmodium falciparum* within human red blood cells. *Proc Natl Acad Sci U S A* 92, 973-977.
- Yuthavong, Y., 2002. Basis for antifolate action and resistance in malaria. *Microbes Infect* 4, 175-182.
- Yuvaniyama, J., Chitnumsub, P., Kamchonwongpaisan, S., Vanichtanankul, J., Sirawaraporn, W., Taylor, P., Walkinshaw, M.D., Yuthavong, Y., 2003. Insights into antifolate resistance from malarial DHFR-TS structures. *Nat Struct Biol* 10, 357-365.
- Zaccolo, M., Williams, D.M., Brown, D.M., Gherardi, E., 1996. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. *J Mol Biol* 255, 589-603.

APPENDICES

Appendix A

Preparation of some reagents and buffers

1. Preparation of media for *E.coli*

1.1. LB (Luria-Bertani) medium (1L)

Bacto-tryptone	10 g
Bacto-yeast extract	5 g
NaCl	10 g

Stir until the ingredients have dissolved. Adjust the final volume to 1 L with distilled water (For LB plate agar, add 15 g for Bacto-agar per liter). Autoclave at 15 psi (120°C for 20 min)

2. Preparation of solutions and buffers for *P. berghei* culture

2.1. Complete culture medium

Culture medium: RPMI1640 with L-glutamine and 4.95 g HEPES per liter culture medium

Preparation of medium:

- dissolve 10.41 g RPMI 1640 medium in 1 L water (add powder slowly under continuous stirring)
- add 2 g NaHCO₃ and 4.95 g HEPES
- add 50.000 I.U. Neomycin (stock-solution of 10.000 I.U. /ml; Gibco)
- sterilize by filtration through a 0.2 µm sieve

- store at -20°C

- immediately prior to use, fetal bovine serum is added at a final concentration of 25% (v/v) to give complete culture medium

2.2. Nycodenz stock solution

- dissolve 138 g Nycodenz-powder in 500 ml buffered medium (see below) (density 1.15 g/ml at 20°C)

- autoclave for 20 min at 120°C and store at 4°C

Buffered medium:

- 5 mM Tris/HCl 605.7 mg/l, pH 7.5

- 3 mM KCl 223.7 mg/l

- 0.3 mM Ca Na₂EDTA 112.3 mg/l

2.3. Pyrimethamine-solution for intraperitoneal injection

Dissolve pyrimethamine in DMSO to a desirable stock solution. Dilute the stock solution 20 times with PBS to 5%DMSO for avoiding DMSO toxicity in mice.

2.4. *P. berghei* freezing solution

30% glycerol in PBS. Autoclave

2.5. Parasite lysis buffer

10 mM Tris pH8.0, 0.4 M NaCl, 1 mM EDTA, 1%SDS

2.6. 0.2% Saponin

Dissolve 0.2 g saponin in 100 ml RPMI-Hepes, filter sterilise and store at 4°C

3. Preparation of solutions for Southern blot analysis

3.1. 10X Maleic Acid Buffer

For 500ml:

58 g Maleic Acid (final conc. 10M)

43.8 g NaCl (final conc. 1.5M)

adjust the pH to 7.5 with NaOH (pH changes quickly)

Autoclave

3.2. 1X Maleic Acid Buffer

Dilute the 10 x Maleic Acid Buffer in DDW

3.3. 20X SSC

For 1 liter

175.3 g NaCl (final conc. 3M)

88.2 g Sodium Citrate-2H₂O (final conc. 0.3M)

3.4. Washing Buffer

1 x Maleic Acid, 0.3% Tween 20

3.5. Denharts Hybridization Solution

6X SSC, 5X Denharts, 0.1%SDS

3.6. 10X Blocking Solution

Dissolve Blocking Reagent 10% (w/v). (bottle 4 of DIG kit) in 1X Maleic Acid Buffer at 65°C. Place on stirrer and mix. Autoclave and store at 4°C.

3.7. 1X Blocking Solution

Dilute the 10X Blocking Solution with 1X Maleic Acid. Store at 4°C

3.8. Detection Buffer

0.1 M Tris HCl, 0.1 M NaCl, pH 9.5

3.9. CSPD (vial 5) 100X

Thaw 100X CSPD (vial 5 from DIG kit) when the kit arrives and make 20 μ l aliquots. Freeze these aliquots. Avoid repeated freeze/thaw cycles. Twenty microliter diluted 1:100 with Detection Buffer make up 2 ml (enough for the chemiluminescent detection of a 10 \times 10 cm membrane).

Appendix B

ED₅₀ of pyrimethamine against transgenic parasites

Table S-1 Mean ED₅₀ of pyrimethamine against PbGFP, *PbPfS108N*, *PbPfDHFR3m1* and *PbPfDHFR3m2* transgenic parasites.

Parasite line	ED ₅₀ value (mg/kg)			Mean of ED ₅₀ ± SD.
	Exp. I	Exp.	Exp.	
PbGFP	0.01	0.02	0.02	0.02 ± 0.01
<i>PbPfS108N</i>	1.10	0.84	1.30	1.08 ± 0.23
<i>PbPfDHFR3m1</i>	2.35	1.52	0.96	1.61 ± 0.70
<i>PbPfDHFR3m2</i>	1.53	0.83	0.87	1.07 ± 0.39

Appendix C

Point mutations of DHFR enzymes that confer resistance to antifolate drugs

Table S-2 Point mutations of DHFR enzymes that confer resistance to antifolate drugs found in transgenic parasites *PbPfd*DHFR3m1 and *PbPfd*DHFR3m2 and in previously reported non-*Plasmodium* system and field isolates.

Parasite line	Mutations of DHFR	References
<i>PbPfd</i> DHFR3m1 (M55I+S108N+S189C)	M55 corresponds to F31 of <i>h</i> DHFR. F31A, F31G, F31S	(Chunduru et al., 1994)
	F31P	(Volpato et al., 2007)
	F31R	(Patel et al., 1997)
	N51I+S108N+S189R	(Ferlan et al., 2001)
<i>PbPfd</i> DHFR3m2 (C50Y+S108N+F116S)	C50R+N51I+S108N+ DHPS mutation (A437G+K540E+A581G)	(Vasconcelos et al., 2000)
	C50R+N51I+S108N+I164L+ BR+DHPS mutation (A437G+K540E+A581G)	
	N51I+C59R+S108N+C50S	(Hankins et al., 2001)
	C50Y, C50N, C50S	(Japrun et al., 2007)

Table S-2 Point mutations of DHFR enzymes that confer resistance to antifolate drugs found in transgenic parasites *PbPfdHFR3m1* and *PbPfdHFR3m2* and in previously reported non-*Plasmodium* system and field isolates (continued).

Parasite line	Mutations of DHFR	References
	C50R, C50R+C59R	(Chusacultanachai et al., 2002)

BR: Bolivia repeat, a five amino acid repeat insertion between codons 30 and 31.



CURRICULUM VITAE

NAME	Miss Wachiraporn Tipsuwan
Date of Birth	June 4, 1972
Instituted attend	
March, 1994	Bachelor of Nursing Mahidol University, Thailand
August, 2004	Master of Science (Biochemistry) Chiang Mai University

